Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

Lilly, ImmuNext in preclinical autoimmune pact

March 27, 2019 1:59 PM UTC

ImmuNext granted Lilly an exclusive, worldwide license to an undisclosed preclinical target to treat autoimmune diseases. The partners said they intend to develop an antibody targeting the metabolism of lymphocytes.

ImmuNext Inc. (Lebanon, N.H.) will receive $40 million up front and is eligible for $565 million in milestones, plus royalties. Eli Lilly and Co. (NYSE:LLY) and ImmuNext also established a three-year collaborative research deal to explore the target...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article

BCIQ Company Profiles

Eli Lilly and Co.

Immunext Inc.